title: Dosing time-dependent pharmacological effects of anti-metabolites for rat cardiac graft.
abstract: Antimetabolites such as methotrexete and 6-mercaptopurine have been shown to have circadian variations in their toxicities. However, chronopharmacological profiles of mizoribine (Miz) that is newly synthesized as an anti-metabolic agent for immunosuppression, have not been evaluated. In this study, we examined the dosing time-dependent alterations in the pharmacokinetics and pharmacodynamics of Miz. In addition, chronopharmacology of azathiopurine (Aza) was also evaluated to compare with that of Miz. Initially, Miz (10 and 20 mg/kg) or Aza (20 mg/kg) was orally administered at 8:00 hr or 20:00 hr for 3 weeks to rats. To reveal the dosing time-dependent difference of pharmacokinetics, Miz (20 mg/kg) was orally given at 8:00 hr or 20:00 hr and blood was obtained for 12 hours. Finally, Miz (20 mg/kg) or Aza (20 mg/kg) was administered at 8:00 hr or 20:00 hr to rats with heterotopic allogeneic heart grafts. The Miz group treated at 8:00 hr and Aza group treated at 20:00 hr showed severe myelosuppression compared with their each opposite dosing time. AUC of Miz in the morning trial was twice as high as that in the evening trial. The graft survival durations of the Miz- and Aza-treated groups were significantly longer than those of the respective control groups, but were not affected by dosing time of each agent. These results suggest that the toxicity, but not efficacy of Miz is varied with the dosing time. The chronotoxicological phenomenon of Miz might be, at least in part, explained by the dosing time-dependent difference in serum drug concentrations and apparent clearance.
authors.affiliation: Department of Clinical Pharmacokinetics, Division of Pharmaceutical Sciences, Graduate School of Kyushu University, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: To
authors.forename: D R
authors.initials: DR
authors.lastname: Xiu
authors.forename: S
authors.initials: S
authors.lastname: Hishikawa
authors.forename: H
authors.initials: H
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Sudoh
authors.forename: K
authors.initials: K
authors.lastname: Sunaga
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
authors.forename: A
authors.initials: A
authors.lastname: Fujimura
authors.forename: E
authors.initials: E
authors.lastname: Kobayashi
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001379:Azathioprine / Q000008:administration & dosage / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006085:Graft Survival; D006207:Half-Life; D016027:Heart Transplantation; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D012263:Ribonucleosides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D001379:Azathioprine